Allogene Therapeutics, Inc. Operating Income
Allogene Therapeutics, Inc. (ALLO) reported Operating Income of -$46.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-12
- Allogene Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$46.92M.
- Allogene Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$46.09M.
- Allogene Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$42.40M.
- Allogene Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$44.90M.
- Allogene Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$209.31M.
- Allogene Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$273.20M.
- Allogene Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$327.74M.
- Allogene Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$335.54M.
| Period end | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$46.92M 10-Q · filed 2026-08-12 | -$93.01M 10-Q · filed 2026-08-12 | -$135.42M derived: sum of 3 quarters · filed 2026-08-12 | -$180.32M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2026-03-31 | -$46.09M 10-Q · filed 2026-05-13 | -$88.50M derived: sum of 2 quarters · filed 2026-05-13 | -$133.40M derived: sum of 3 quarters · filed 2026-05-13 | -$190.22M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-12-31 | -$42.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$87.31M derived: sum of 2 quarters · filed 2026-03-12 | -$144.12M derived: sum of 3 quarters · filed 2026-08-12 | -$209.31M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | -$44.90M 10-Q · filed 2025-11-06 | -$101.72M derived: sum of 2 quarters · filed 2026-08-12 | -$166.91M 10-Q · filed 2025-11-06 | -$227.40M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-06-30 | -$56.82M 10-Q · filed 2026-08-12 | -$122.01M 10-Q · filed 2026-08-12 | -$182.50M derived: sum of 3 quarters · filed 2026-08-12 | -$254.27M derived: sum of 4 quarters · filed 2026-08-12 | |||||
| 2025-03-31 | -$65.19M 10-Q · filed 2026-05-13 | -$125.68M derived: sum of 2 quarters · filed 2026-05-13 | -$197.46M derived: sum of 3 quarters · filed 2026-05-13 | -$268.89M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | -$60.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$132.26M derived: sum of 2 quarters · filed 2026-03-12 | -$203.69M derived: sum of 3 quarters · filed 2026-03-12 | -$273.20M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | -$71.77M 10-Q · filed 2025-11-06 | -$143.21M derived: sum of 2 quarters · filed 2025-11-06 | -$212.71M 10-Q · filed 2025-11-06 | -$297.82M derived: sum of 4 quarters · filed 2025-11-06 | |||||
| 2024-06-30 | -$71.43M 10-Q · filed 2025-08-13 | -$140.94M 10-Q · filed 2025-08-13 | -$226.04M derived: sum of 3 quarters · filed 2025-08-13 | -$289.04M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$69.50M 10-Q · filed 2025-05-13 | -$154.61M derived: sum of 2 quarters · filed 2025-05-13 | -$217.61M derived: sum of 3 quarters · filed 2025-05-13 | -$298.15M derived: sum of 4 quarters · filed 2025-05-13 | |||||
| 2023-12-31 | -$85.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$148.10M derived: sum of 2 quarters · filed 2025-03-13 | -$228.65M derived: sum of 3 quarters · filed 2025-03-13 | -$327.74M 10-K · filed 2025-03-13 | |||||
| 2023-09-30 | -$63.00M 10-Q · filed 2024-11-07 | -$62.98M 10-Q · filed 2023-11-02 | -$143.54M derived: sum of 2 quarters · filed 2024-11-07 | -$242.63M 10-Q · filed 2024-11-07 | -$242.56M 10-Q · filed 2023-11-02 | -$339.02M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | -$80.54M 10-Q · filed 2024-08-07 | -$80.52M 10-Q · filed 2023-08-02 | -$179.63M 10-Q · filed 2024-08-07 | -$179.59M 10-Q · filed 2023-08-02 | -$276.03M derived: sum of 3 quarters · filed 2024-08-07 | -$358.54M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | -$99.09M 10-Q · filed 2024-05-13 | -$99.07M 10-Q · filed 2023-05-03 | -$195.49M derived: sum of 2 quarters · filed 2024-05-13 | -$278.00M derived: sum of 3 quarters · filed 2024-05-13 | -$354.61M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | -$96.39M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | -$178.91M derived: sum of 2 quarters · filed 2024-03-14 | -$255.52M derived: sum of 3 quarters · filed 2024-03-14 | -$335.54M 10-K/A · filed 2024-03-14 | -$335.45M 10-K · filed 2023-02-28 | ||||
| 2022-09-30 | -$82.51M 10-K · filed 2024-03-14 | -$82.49M 10-Q · filed 2022-11-02 | -$159.13M derived: sum of 2 quarters · filed 2024-03-14 | -$239.14M 10-K · filed 2024-03-14 | -$239.07M 10-Q · filed 2022-11-02 | -$237.43M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | -$76.62M 10-K · filed 2024-03-14 | -$76.59M 10-Q · filed 2022-08-09 | -$156.63M 10-K · filed 2024-03-14 | -$156.59M 10-Q · filed 2022-08-09 | -$154.92M derived: sum of 3 quarters · filed 2024-03-14 | -$232.59M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | -$80.01M 10-K · filed 2024-03-14 | -$79.99M 10-Q · filed 2022-05-04 | -$78.31M derived: sum of 2 quarters · filed 2024-03-14 | -$155.98M derived: sum of 3 quarters · filed 2024-03-14 | -$227.01M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-12-31 | $1.71M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$75.96M derived: sum of 2 quarters · filed 2024-03-14 | -$146.99M derived: sum of 3 quarters · filed 2024-03-14 | -$180.19M 10-K/A · filed 2024-03-14 | -$255.79M 10-K · filed 2022-02-23 | ||||
| 2021-09-30 | -$77.67M 10-Q · filed 2022-11-02 | -$148.70M derived: sum of 2 quarters · filed 2022-11-02 | -$181.90M 10-Q · filed 2022-11-02 | -$251.26M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-06-30 | -$71.03M 10-Q · filed 2022-08-09 | -$104.23M 10-Q · filed 2022-08-09 | -$173.59M derived: sum of 3 quarters · filed 2024-03-14 | -$241.63M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-03-31 | -$33.20M 10-Q · filed 2022-05-04 | -$102.56M derived: sum of 2 quarters · filed 2024-03-14 | -$170.60M derived: sum of 3 quarters · filed 2024-03-14 | -$233.76M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2020-12-31 | -$69.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | -$137.40M derived: sum of 2 quarters · filed 2024-03-14 | -$200.56M derived: sum of 3 quarters · filed 2024-03-14 | -$258.24M 10-K/A · filed 2024-03-14 | |||||
| 2020-09-30 | -$68.04M 10-Q · filed 2021-11-04 | -$131.20M derived: sum of 2 quarters · filed 2021-11-04 | -$188.88M 10-Q · filed 2021-11-04 | -$253.46M derived: sum of 4 quarters · filed 2021-11-04 | |||||
| 2020-06-30 | -$63.16M 10-Q · filed 2021-08-04 | -$120.84M 10-Q · filed 2021-08-04 | -$185.42M derived: sum of 3 quarters · filed 2021-08-04 | -$240.43M derived: sum of 4 quarters · filed 2021-08-04 | |||||
| 2020-03-31 | -$57.68M 10-Q · filed 2021-05-05 | -$122.26M derived: sum of 2 quarters · filed 2021-05-05 | -$177.27M derived: sum of 3 quarters · filed 2021-05-05 | -$223.23M derived: sum of 4 quarters · filed 2021-05-05 | |||||
| 2019-12-31 | -$64.58M 10-K · filed 2020-02-27 | -$119.59M derived: sum of 2 quarters · filed 2020-11-04 | -$165.55M derived: sum of 3 quarters · filed 2020-11-04 | -$202.01M 10-K · filed 2022-02-23 | |||||
| 2019-09-30 | -$55.01M 10-Q · filed 2020-11-04 | -$100.97M derived: sum of 2 quarters · filed 2020-11-04 | -$137.43M 10-Q · filed 2020-11-04 | -$170.48M derived: sum of 4 quarters · filed 2020-11-04 | |||||
| 2019-06-30 | -$45.96M 10-Q · filed 2020-08-05 | -$82.42M 10-Q · filed 2020-08-05 | -$115.47M derived: sum of 3 quarters · filed 2020-08-05 | -$137.66M derived: sum of 4 quarters · filed 2020-08-05 | |||||
| 2019-03-31 | -$36.46M 10-Q · filed 2020-05-06 | -$69.51M derived: sum of 2 quarters · filed 2020-05-06 | -$91.69M derived: sum of 3 quarters · filed 2020-05-06 | -$226.71M derived: sum of 4 quarters · filed 2020-05-06 | |||||
| 2018-12-31 | -$33.05M 10-K · filed 2020-02-27 | $33.05M 10-K · filed 2019-03-08 | -$55.23M derived: sum of 2 quarters · filed 2020-02-27 | -$190.25M derived: sum of 3 quarters · filed 2020-02-27 | -$192.84M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$22.19M 10-K · filed 2020-02-27 | -$157.20M derived: sum of 2 quarters · filed 2020-02-27 | -$159.80M 10-Q · filed 2019-11-05 | ||||||
| 2018-06-30 | -$135.01M 10-K · filed 2020-02-27 | $135.01M 10-K · filed 2019-03-08 | -$137.61M 10-Q · filed 2019-08-07 | ||||||
| 2018-03-31 | -$2.60M 10-K · filed 2020-02-27 | $2.60M 10-K · filed 2019-03-08 | |||||||
| 2017-12-31 | -$2.00K 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |